AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23294276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 23539703 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal chevron osteotomy with lateral soft-tissue release
Number of subjects: 110
Study 23539703 — intervention group
Group type: COMPARATOR
Intervention: Distal chevron osteotomy with lateral soft-tissue release
Number of subjects: 110
Study 20622529 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 1771
Study 18374841 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (1-4 mg per day)
Number of subjects: 498
Study 18374841 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg per day)
Number of subjects: 498
Study 18374841 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg per day)
Number of subjects: 498
Study 18374841 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200-750 mg per day)
Number of subjects: 498
Study 18374841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg per day)
Number of subjects: 498
Study 16326171 — intervention group
Group type: EXPERIMENTAL
Intervention: EGG diet (640 mg/d cholesterol)
Number of subjects: 91
Study 16326171 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet (0 mg/d cholesterol)
Number of subjects: 91
Study 16326171 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 SstI polymorphism analysis
Number of subjects: 91
Study 16326171 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 genotype comparison
Number of subjects: 91
Study 14744358 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate (Dermabond)
Number of subjects: 59
Study 14744358 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular skin sutures (4-0 absorbable suture)
Number of subjects: 59
Study 14744358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 59
Study 11386203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep fragmentation
Number of subjects: 8
Study 11386203 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed study nights
Number of subjects: 8
Study 9350925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 567
Study 9350925 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 567
Study 8237930 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat probe
Number of subjects: 80
Study 8237930 — intervention group
Group type: COMPARATOR
Intervention: Ethanol injection
Number of subjects: 80
Study 8237930 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system
Number of subjects: 80
Study 8237930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-endoscopy and post-endoscopy scores
Number of subjects: 80
Study 8237930 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent illnesses
Number of subjects: 80
Study 8237930 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stigmata
Number of subjects: 80
Study 4008112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 18
Study 4008112 — intervention group
Group type: COMPARATOR
Intervention: Propranolol retard 160 mg
Number of subjects: 18
Study 30916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative oliguria (urinary output <0.5 ml kg‐1 h‐1)
Number of subjects: 2444
Study 30916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative oliguria (urinary output <0.3 ml kg‐1 h‐1)
Number of subjects: 2444
Study 30916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliguria presence
Number of subjects: 2444
Study 30916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliguria absence
Number of subjects: 2444
Study 26070528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with lercanidipine (LER, 10-20mg)
Number of subjects: 76
Study 26070528 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with hydrochlorothiazide (HCT, 12.5-25mg)
Number of subjects: 76
Study 25956055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive home-based training delivered through the internet for 30 min daily for 20 weeks
Number of subjects: 34
Study 25956055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervening training)
Number of subjects: 34
Study 25956055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive home-based training
Number of subjects: 34
Study 23313977 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 42
Study 23313977 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 42
Study 21240029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-event massage
Number of subjects: 0
Study 21240029 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (detuned ultrasound)
Number of subjects: 0
Study 19101456 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvanted vaccine
Number of subjects: 270
Study 19101456 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B virus (HBV) control vaccine
Number of subjects: 270
Study 16039825 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depression (MD)
Number of subjects: 122
Study 16039825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Dependence
Number of subjects: 122
Study 16039825 — intervention group
Group type: COMPARATOR
Intervention: Control (nonabusers)
Number of subjects: 122
Study 12612226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI meal replacement (LMR)
Number of subjects: 16
Study 12612226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI whole-food meal (LWM)
Number of subjects: 16
Study 12612226 — intervention group
Group type: COMPARATOR
Intervention: Moderately high-GI meal replacement (HMR)
Number of subjects: 16
Study 10715924 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued aspirin therapy (100 mg daily)
Number of subjects: 39
Study 10715924 — intervention group
Group type: COMPARATOR
Intervention: Stopped aspirin therapy (1 week before procedure)
Number of subjects: 39
Study 8938912 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 178
Study 1584314 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment at 300 U/kg body weight i.v. once a week for 3 months
Number of subjects: 12
Study 1584314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 1584314 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 12
Study 1584314 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment and Control group
Number of subjects: 12
Study 3156621 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone given pre- and post-operatively
Number of subjects: 0
Study 3156621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 0
Study 3156621 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 29727404 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg)
Number of subjects: 13
Study 29727404 — intervention group
Group type: EXPERIMENTAL
Intervention: p-Synephrine (3 mg·kg)
Number of subjects: 13
Study 29727404 — intervention group
Group type: EXPERIMENTAL
Intervention: p-Synephrine + Caffeine (3 mg·kg each)
Number of subjects: 13
Study 29727404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27173084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 2012
Study 27173084 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 2012
Study 24456716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutonix DCB (2 μg/mm² paclitaxel)
Number of subjects: 101
Study 24456716 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloons (control)
Number of subjects: 101
Study 24456716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutonix DCB
Number of subjects: 101
Study 22901000 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives users (20-30 years)
Number of subjects: 200
Study 22901000 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives users (31-40 years)
Number of subjects: 200
Study 22901000 — intervention group
Group type: COMPARATOR
Intervention: Control group (20-30 years)
Number of subjects: 200
Study 22901000 — intervention group
Group type: COMPARATOR
Intervention: Control group (31-40 years)
Number of subjects: 200
Study 20331335 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (PFT) endotracheal tube
Number of subjects: 40
Study 20331335 — intervention group
Group type: COMPARATOR
Intervention: Standard-tip endotracheal tube (ETT)
Number of subjects: 40
Study 17624365 — intervention group
Group type: EXPERIMENTAL
Intervention: One learning trial
Number of subjects: 0
Study 17624365 — intervention group
Group type: EXPERIMENTAL
Intervention: Two learning trials
Number of subjects: 0
Study 17624365 — intervention group
Group type: EXPERIMENTAL
Intervention: Four learning trials
Number of subjects: 0
Study 17624365 — intervention group
Group type: EXPERIMENTAL
Intervention: Three learning trials
Number of subjects: 0
Study 17624365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating learning and test trials
Number of subjects: 0
Study 15868230 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol hyaluronate/carboxymethylcellulose membrane
Number of subjects: 120
Study 15868230 — intervention group
Group type: COMPARATOR
Intervention: No anti-adhesion treatment (control)
Number of subjects: 120
Study 15868230 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol hyaluronate/carboxymethylcellulose
Number of subjects: 120
Study 11932569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g.kg‐1 body mass)
Number of subjects: 7
Study 11932569 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) (Control)
Number of subjects: 7
Study 9798800 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 20 mg/kg/day
Number of subjects: 61
Study 9798800 — intervention group
Group type: COMPARATOR
Intervention: UDCA 10 mg/kg/day
Number of subjects: 61
Study 9128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy (BTM): bismuth subnitrate 75 mg q.i.d., oxytetracycline 500 mg q.i.d., metronidazole 400 mg b.i.d. for 14 days
Number of subjects: 100
Study 9128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-based triple therapy (OAM): omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., metronidazole 400 mg b.i.d. for 14 days
Number of subjects: 100
Study 9128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy (BTM) in nonrandomized group with metronidazole-resistant strains
Number of subjects: 100
Study 9128317 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-based triple therapy (OAM) in nonrandomized group with metronidazole-resistant strains
Number of subjects: 100
Study 1764944 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and folic acid supplementation
Number of subjects: 59
Study 7054901 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb-sparing surgery plus radiation therapy plus chemotherapy
Number of subjects: 26
Study 7054901 — intervention group
Group type: COMPARATOR
Intervention: Amputation plus chemotherapy
Number of subjects: 26
Study 31403507 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (N2O)
Number of subjects: 51
Study 31403507 — intervention group
Group type: COMPARATOR
Intervention: Control group (without N2O)
Number of subjects: 51
Study 30650266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic Acid Cream (FAC) alone for mild acne (39 cases)
Number of subjects: 186
Study 30650266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic Acid Cream (FAC) combined with minocycline hydrochloride for severe acne (64 cases)
Number of subjects: 186
Study 30650266 — intervention group
Group type: EXPERIMENTAL
Intervention: Longzhu Ointment (LO) alone for mild acne (27 cases)
Number of subjects: 186
Study 30650266 — intervention group
Group type: EXPERIMENTAL
Intervention: Longzhu Ointment (LO) combined with minocycline hydrochloride for severe acne (56 cases)
Number of subjects: 186
Study 30650266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic Acid Cream (FAC)
Number of subjects: 186
Study 30650266 — intervention group
Group type: EXPERIMENTAL
Intervention: Longzhu Ointment (LO)
Number of subjects: 186
Study 30650266 — intervention group
Group type: COMPARATOR
Intervention: Fusidic Acid Cream (FAC) and Longzhu Ointment (LO)
Number of subjects: 186
Study 23841263 — intervention group
Group type: EXPERIMENTAL
Intervention: jieyu granule (JG) combined Paroxetine
Number of subjects: 70
Study 23841263 — intervention group
Group type: COMPARATOR
Intervention: Chinese medical placebo combined Paroxetine
Number of subjects: 70
Study 21116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 45% ethanol and 18% 1-propanol with skin protecting ingredients (Softa-Man®)
Number of subjects: 14
Study 21116645 — intervention group
Group type: COMPARATOR
Intervention: Product in the absence of cosmetic additives
Number of subjects: 14
Study 21116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (with and without additives)
Number of subjects: 14
Study 19147232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 8
Study 17287680 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS) with protection
Number of subjects: 844
Study 17287680 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty and stenting (CAS) without protection
Number of subjects: 844
Study 15474717 — intervention group
Group type: EXPERIMENTAL
Intervention: Td5aP-IPV
Number of subjects: 0
Study 15474717 — intervention group
Group type: EXPERIMENTAL
Intervention: Td5aP + OPV
Number of subjects: 0
Study 15474717 — intervention group
Group type: COMPARATOR
Intervention: DT2aP-IPV (control)
Number of subjects: 0
Study 11506402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days
Number of subjects: 32
Study 11506402 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone tapering from 60 mg to 10 mg daily over six weeks
Number of subjects: 32
Study 11506402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 32
Study 11506402 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 32
Study 9420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 250 mg
Number of subjects: 24
Study 9420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (RIF) 600 mg
Number of subjects: 24
Study 9420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA) 1500 mg
Number of subjects: 24
Study 8493625 — intervention group
Group type: COMPARATOR
Intervention: BRL 38227 (0.125, 0.25, and 0.5 mg)
Number of subjects: 17
Study 8493625 — intervention group
Group type: COMPARATOR
Intervention: BRL 38227 (0.125 and 0.5 mg)
Number of subjects: 17
Study 8493625 — intervention group
Group type: COMPARATOR
Intervention: BRL 38227 (0.5 mg)
Number of subjects: 17
Study 8493625 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol (8 mg)
Number of subjects: 17
Study 3104624 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel at a dose of 40 mg kg‐1
Number of subjects: 0
Study 3104624 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate at 10 mg kg‐1 (three fortnightly doses)
Number of subjects: 0
Study 3104624 — intervention group
Group type: COMPARATOR
Intervention: Single dose of metrifonate
Number of subjects: 0
Study 3104624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metrifonate (10 mg kg‐1) and niridazole (25 mg kg‐1)
Number of subjects: 0
Study 3104624 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of praziquantel
Number of subjects: 0
Study 3104624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metrifonate (10 mg kg‐1) and praziquantel (10 mg kg‐1)
Number of subjects: 0
Study 30082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 0
Study 27923057 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified cereal supplement (FG)
Number of subjects: 410
Study 27923057 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-based complementary food (MG)
Number of subjects: 410
Study 27923057 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cereal supplement (LG)
Number of subjects: 410
Study 24462043 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g/d of white fish (Namibia hake) with advice on a healthy diet
Number of subjects: 273
Study 24462043 — intervention group
Group type: COMPARATOR
Intervention: No fish or seafood with advice on a healthy diet
Number of subjects: 273
Study 22748447 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Number of subjects: 326
Study 22748447 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant sleep problems (transient, recurring, or persistent)
Number of subjects: 326
Study 20470283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily for 2 months
Number of subjects: 32
Study 20470283 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 healthy subjects)
Number of subjects: 32
Study 18331436 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (6 g/day containing 160 mg of eicosapentaenic acid and 100 mg of docosahexaenoic acid)
Number of subjects: 69
Study 18331436 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (n-6) as control
Number of subjects: 69
Study 15990609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT)
Number of subjects: 25
Study 15990609 — intervention group
Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 25
Study 15990609 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of 10 microm in CCT
Number of subjects: 25
Study 15990609 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 10 microm in CCT
Number of subjects: 25
Study 14696018 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 50 mg twice a day plus pindolol 2.5 mg three times a day
Number of subjects: 80
Study 14696018 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran 50 mg twice a day plus placebo three times a day
Number of subjects: 80
Study 10484948 — intervention group
Group type: EXPERIMENTAL
Intervention: MacArthur Competence Assessment Tool‐Clinical Research (MacCAT‐CR)
Number of subjects: 26
Study 10484948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale
Number of subjects: 26
Study 10484948 — intervention group
Group type: EXPERIMENTAL
Intervention: MacCAT‐CR
Number of subjects: 26
Study 8601365 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodiol, 1200 mg/day
Number of subjects: 47
Study 8601365 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen, 1600 mg/day
Number of subjects: 47
Study 8601365 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 1987534 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sucrose solution (2 mL) prior to blood collection
Number of subjects: 0
Study 1987534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-flavored pacifier prior to and during circumcision
Number of subjects: 0
Study 1987534 — intervention group
Group type: COMPARATOR
Intervention: Water-moistened pacifier prior to and during circumcision
Number of subjects: 0
Study 1987534 — intervention group
Group type: COMPARATOR
Intervention: Control group (sterile water for blood collection)
Number of subjects: 0
Study 1987534 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard circumcision without intervention)
Number of subjects: 0
Study 6344181 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sustained release tablet containing norephedrine
Number of subjects: 30
Study 6344181 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 30
Study 31988257 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunised physicians diagnosing subjected-to-bias vignettes
Number of subjects: 91
Study 31988257 — intervention group
Group type: COMPARATOR
Intervention: Non-immunised physicians diagnosing subjected-to-bias vignettes
Number of subjects: 91
Study 31988257 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunised physicians diagnosing not-subjected-to-bias vignettes
Number of subjects: 91
Study 31988257 — intervention group
Group type: COMPARATOR
Intervention: Non-immunised physicians diagnosing not-subjected-to-bias vignettes
Number of subjects: 91
Study 31988257 — intervention group
Group type: COMPARATOR
Intervention: Non-immunised physicians comparing subjected-to-bias and not-subjected-to-bias vignettes
Number of subjects: 91
Study 30219394 — intervention group
Group type: EXPERIMENTAL
Intervention: High longitudinal systolic stretch index (SSI) ≥ group median of 3.1%
Number of subjects: 442
Study 30219394 — intervention group
Group type: EXPERIMENTAL
Intervention: High longitudinal systolic stretch index (SSI) ≥ group median of 2.6% among patients with QRS 120 to 149 ms or non‐LBBB
Number of subjects: 442
Study 30219394 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS)
Number of subjects: 442
Study 30428238 — intervention group
Group type: COMPARATOR
Intervention: No hydration (NH)
Number of subjects: 12
Study 30428238 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of fluid loss during immersion (RD)
Number of subjects: 12
Study 30428238 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of fluid after immersion (RA)
Number of subjects: 12
Study 30428238 — intervention group
Group type: EXPERIMENTAL
Intervention: Run times
Number of subjects: 12
Study 30428238 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to orthostasis during the HUTT
Number of subjects: 12
Study 30428238 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight heart rate variability and blood pressures
Number of subjects: 12
Study 26681757 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy
Number of subjects: 686
Study 26681757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 686
Study 25100891 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy (administered once a day for 1 hour for 8 weeks)
Number of subjects: 64